These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 15607318)
1. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns. Janković MM; Kosanović MM Clin Biochem; 2005 Jan; 38(1):58-65. PubMed ID: 15607318 [TBL] [Abstract][Full Text] [Related]
2. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Ohyama C; Hosono M; Nitta K; Oh-eda M; Yoshikawa K; Habuchi T; Arai Y; Fukuda M Glycobiology; 2004 Aug; 14(8):671-9. PubMed ID: 15044396 [TBL] [Abstract][Full Text] [Related]
3. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Fukushima K; Satoh T; Baba S; Yamashita K Glycobiology; 2010 Jan; 20(4):452-60. PubMed ID: 20008118 [TBL] [Abstract][Full Text] [Related]
4. A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. Dwek MV; Jenks A; Leathem AJ Clin Chim Acta; 2010 Dec; 411(23-24):1935-9. PubMed ID: 20708609 [TBL] [Abstract][Full Text] [Related]
5. Sialylation and fucosylation of cancer-associated prostate specific antigen. Kosanović MM; Janković MM J BUON; 2005; 10(2):247-50. PubMed ID: 17343337 [TBL] [Abstract][Full Text] [Related]
6. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264 [TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. Chen Z; Chen H; Stamey TA J Urol; 1997 Jun; 157(6):2166-70. PubMed ID: 9146608 [TBL] [Abstract][Full Text] [Related]
8. Molecular forms and microheterogeneity of the oligosaccharide chains of pregnancy-associated CA125 antigen. Jankovic MM; Tapuskovic BS Hum Reprod; 2005 Sep; 20(9):2632-8. PubMed ID: 15905287 [TBL] [Abstract][Full Text] [Related]
9. Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer. Barrabés S; Llop E; Ferrer-Batallé M; Ramírez M; Aleixandre RN; Perry AS; de Llorens R; Peracaula R Clin Chim Acta; 2017 Jul; 470():97-102. PubMed ID: 28495148 [TBL] [Abstract][Full Text] [Related]
10. Strategy for sensitive and specific detection of molecular forms of PSA based on 2DE and kinetic analysis: a step towards diagnosis of prostate cancer. Kumar V; Hassan MI; Singh AK; Dey S; Singh TP; Yadav S Clin Chim Acta; 2009 May; 403(1-2):17-22. PubMed ID: 19118539 [TBL] [Abstract][Full Text] [Related]
11. Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera. Totten SM; Adusumilli R; Kullolli M; Tanimoto C; Brooks JD; Mallick P; Pitteri SJ Sci Rep; 2018 Apr; 8(1):6509. PubMed ID: 29695737 [TBL] [Abstract][Full Text] [Related]
12. Clinical utility of the interaction between lectin and serum prostate specific antigen in prostate cancer. Batabyal SK; Majhi R; Basu PS Neoplasma; 2009; 56(1):68-71. PubMed ID: 19152248 [TBL] [Abstract][Full Text] [Related]
13. TP53 mutation in prostate needle biopsies--comparison with patients follow-up. Ecke TH; Schlechte HH; Hübsch A; Lenk SV; Schiemenz K; Rudolph BD; Miller K Anticancer Res; 2007; 27(6B):4143-8. PubMed ID: 18225585 [TBL] [Abstract][Full Text] [Related]
14. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging. Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354 [TBL] [Abstract][Full Text] [Related]
15. Glycosylation of prostate specific antigen and its potential diagnostic applications. Vermassen T; Speeckaert MM; Lumen N; Rottey S; Delanghe JR Clin Chim Acta; 2012 Oct; 413(19-20):1500-5. PubMed ID: 22722018 [TBL] [Abstract][Full Text] [Related]
16. Isoforms of prostate-specific antigen in serum: a result of the glycosylation process in dysplastic prostatic cells? Jung K; Lein M; Henke W; Schnorr D; Loening SA Prostate; 1996 Jul; 29(1):65-6. PubMed ID: 8685058 [No Abstract] [Full Text] [Related]
17. Percent free PSA as an additional measure in a prostate cancer screen. Miele ME Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982 [TBL] [Abstract][Full Text] [Related]
18. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography. Wu P; Stenman UH; Pakkala M; Närvänen A; Leinonen J Prostate; 2004 Mar; 58(4):345-53. PubMed ID: 14968435 [TBL] [Abstract][Full Text] [Related]
19. Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer. Bouraoui Y; Ricote M; García-Tuñón I; Rodriguez-Berriguete G; Touffehi M; Rais NB; Fraile B; Paniagua R; Oueslati R; Royuela M Cancer Detect Prev; 2008; 32(1):23-32. PubMed ID: 18400418 [TBL] [Abstract][Full Text] [Related]
20. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia. Zhao Z; Liu J; Li S; Shen W Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]